Clinical Trial Update: A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older [Phase 2]

View source ↗

Summary

Phase 2 study describing the safety and immunogenicity of the IN006 respiratory syncytial virus vaccine in healthy adults aged 60 and older; the trial is active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• IN006

Snippet

Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd | Conditions: Respiratory Syncytial Virus (RSV) Infection | Phase 2 | Status: ACTIVE_NOT_RECRUITING